New Zealand markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.5100+0.0400 (+2.72%)
At close: 04:00PM EST
1.4700 -0.04 (-2.65%)
After hours: 08:00PM EST

Spero Therapeutics, Inc.

675 Massachusetts Avenue
14th Floor
Cambridge, MA 02139
United States
857 242 1600

Full-time employees35

Key executives

NameTitlePayExercisedYear born
Dr. Ankit Mahadevia M.D., MBACo-Founder & Chairman of the Board1.24MN/A1981
Mr. Satyavrat Shukla C.F.A.President, CEO & Director823.27kN/A1972
Ms. Tamara Lynn Joseph L.L.M.Chief Legal Officer & Corporate Secretary775.55kN/A1962
Ms. Esther P. RajaveluCFO & Chief Business OfficerN/AN/A1979
Mr. Timothy KeutzerChief Operating OfficerN/AN/A1968
Ted JenkinsVP & Head of Investor RelationsN/AN/AN/A
Mr. James P. BradyChief Human Resource OfficerN/AN/AN/A
Dr. Kamal Hamed M.B.A., M.D., M.P.H.Chief Medical OfficerN/AN/A1961
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Spero Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.